«

»

Aug 25

APPs lyophilized Oxaliplatin for Injection receives FDA marketing approval APP Pharmaceuticals.

APP’s lyophilized Oxaliplatin for Injection receives FDA marketing approval APP Pharmaceuticals, Inc., a owned subsidiary of Fresenius Kabi Pharmaceuticals Holding wholly, Inc., announced today it received approval from the U comprar .S. Food and Drug Administration to advertise Oxaliplatin for Injection , 50 mg and 100 mg. APP Pharmaceuticals and Fresenius Kabi Oncology Limited are users of the Fresenius Kabi Group of companies. Regarding to IMS data, U.S. According to 2009 IMS data, combined U.S.35 billion..

Food and Drug Administration granted acceptance to advertise the breast cancers treatment medicine to Fresenius Kabi Oncology Small . APP Fresenius and Pharmaceuticals Kabi Oncology Small are members of the Fresenius Kabi Group of companies. Relating to IMS data, 2009 sales of the branded product in the United States were around $916.8 million, with approximately 105 million tablets sold annually. The authorization of Anastrozole further expands APP’s product portfolio in the strategically important Oncology segment, stated John Ducker, president and ceo of APP Pharmaceuticals. We are delighted in order to offer this essential oral medication to new customers in the retail pharmacy channel. .. APP to market Anastrozole 1 mg tablets in U.S.